{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T15:06:11Z","timestamp":1792854371984,"version":"4.5.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,7,29]],"date-time":"2016-07-29T00:00:00Z","timestamp":1469750400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","atherosclerosis-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.atherosclerosis.2016.07.001","type":"journal-article","created":{"date-parts":[[2016,7,4]],"date-time":"2016-07-04T12:57:30Z","timestamp":1467637050000},"page":"248-254","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":65,"special_numbering":"C","title":["Low-density lipoprotein cholesterol levels and lipid-modifying therapy prescription patterns in the real world: An analysis of more than 33,000 high cardiovascular risk patients in Japan"],"prefix":"10.1016","volume":"251","author":[{"given":"Tamio","family":"Teramoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoko","family":"Uno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izuru","family":"Miyoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irfan","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Gorcyca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeto","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Mawatari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoya","family":"Masaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenori","family":"Arai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shizuya","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2016.07.001_bib1","unstructured":"World Health Organization (WHO). Global health estimates for 2000-2012: cause-specific mortality. Available from: URL: http:\/\/www.who.int\/healthinfo\/global_burden_disease\/estimates\/en\/index1.html (Accessed 22.06.16.)."},{"key":"10.1016\/j.atherosclerosis.2016.07.001_bib2","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0140-6736(04)17018-9","article-title":"Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study","volume":"364","author":"Yusuf","year":"2004","journal-title":"Lancet."},{"key":"10.1016\/j.atherosclerosis.2016.07.001_bib3","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Cholesterol Treatment Trialists\u2019 (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2016.07.001_bib4","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","article-title":"ESC\/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European atherosclerosis Society (EAS)","volume":"32","author":"Reiner","year":"2011","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2016.07.001_bib5","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jacl.2013.12.005","article-title":"An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia\u2013full report","volume":"8","author":"Expert Dyslipidemia Panel of the International Atherosclerosis Society Panel members","year":"2014","journal-title":"J.\u00a0Clin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2016.07.001_bib6","doi-asserted-by":"crossref","first-page":"517","DOI":"10.5551\/jat.15792","article-title":"Executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan-2012 version","volume":"20","author":"Teramoto","year":"2013","journal-title":"J.\u00a0Atheroscler. Thromb."},{"key":"10.1016\/j.atherosclerosis.2016.07.001_bib7","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3995\/jstroke.36.144","article-title":"Dyslipidemia and stroke [Japanese]","volume":"36","author":"Kitagawa","year":"2014","journal-title":"Jpn. J. Stroke."},{"key":"10.1016\/j.atherosclerosis.2016.07.001_bib8","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1177\/2047487313480435","article-title":"Comparative benefits of statins in the primary and secondary prevention of major coronary events and all-cause mortality: a network meta-analysis of placebo-controlled and active-comparator trials","volume":"20","author":"Naci","year":"2013","journal-title":"Eur. J. Prev. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2016.07.001_bib9","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1136\/bmj.326.7404.1423","article-title":"Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis","volume":"326","author":"Law","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.atherosclerosis.2016.07.001_bib10","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1001\/jama.2012.366","article-title":"Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis","volume":"307","author":"Boekholdt","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2016.07.001_bib11","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes. IMPROVE-IT Investigators","volume":"372","author":"Cannon","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2016.07.001_bib12","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S0140-6736(06)69472-5","article-title":"Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial","volume":"368","author":"Nakamura","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2016.07.001_bib13","first-page":"S1","article-title":"ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association task force on practice guidelines","author":"Stone","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2016.07.001_bib14","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jacl.2014.07.007","article-title":"National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1-executive summary","volume":"8","author":"Jacobson","year":"2014","journal-title":"J.\u00a0Clin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2016.07.001_bib15","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.atherosclerosis.2012.02.016","article-title":"Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials","volume":"223","author":"Morrone","year":"2012","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2016.07.001_bib16","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.amjcard.2006.08.051","article-title":"Safety and efficacy of statins in Asians","volume":"99","author":"Liao","year":"2007","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2016.07.001_bib17","first-page":"513","article-title":"Predictive value of the low-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio for the prevention of stroke recurrence in Japanese patients treated with rosuvastatin","volume":"32","author":"Igase","year":"2012","journal-title":"Clin. Drug Invest."},{"key":"10.1016\/j.atherosclerosis.2016.07.001_bib18","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1253\/circj.CJ-11-0887","article-title":"Effect of intensive lipid-lowering therapy with rosuvastatin on progression of carotid intima-media thickness in Japanese patients: justification for Atherosclerosis Regression Treatment (JART) study","volume":"76","author":"Nohara","year":"2012","journal-title":"Circ. J."},{"key":"10.1016\/j.atherosclerosis.2016.07.001_bib19","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1536\/ihj.54.33","article-title":"Intensive lipid-lowering therapy for slowing progression as well as inducing regression of atherosclerosis in Japanese patients: subanalysis of the JART study","volume":"54","author":"Yamazaki","year":"2013","journal-title":"Int. Heart J."},{"key":"10.1016\/j.atherosclerosis.2016.07.001_bib20","doi-asserted-by":"crossref","first-page":"152","DOI":"10.5551\/jat.11.152","article-title":"Clinical efficacy and safety of rosuvastatin in Japanese patients with heterozygous familial hypercholesterolemia","volume":"11","author":"Mabuchi","year":"2004","journal-title":"J.\u00a0Atheroscler. Thromb."},{"key":"10.1016\/j.atherosclerosis.2016.07.001_bib21","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.atherosclerosis.2006.11.028","article-title":"Effect of rosuvastatin 5-20mg on triglycerides and other lipid parameters in Japanese patients with hypertriglyceridemia","volume":"194","author":"Saito","year":"2007","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2016.07.001_bib22","doi-asserted-by":"crossref","first-page":"739","DOI":"10.5551\/jat.19109","article-title":"Can intensive lipid-lowering therapy improve the carotid intima-media thickness in Japanese subjects under primary prevention for cardiovascular disease?: the JART and JART extension subanalysis","volume":"21","author":"Daida","year":"2014","journal-title":"J.\u00a0Atheroscler. Thromb."},{"key":"10.1016\/j.atherosclerosis.2016.07.001_bib23","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3400\/avd.oa090019","article-title":"A\u00a0randomized controlled study to compare the effects of rosuvastatin 5 mg and atorvastatin 10 mg on the plasma lipid profile in Japanese patients with hypercholesterolemia (ASTRO-2)","volume":"2","author":"Yamazaki","year":"2009","journal-title":"Ann. Vasc. Dis."},{"key":"10.1016\/j.atherosclerosis.2016.07.001_bib24","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.atherosclerosis.2008.02.008","volume":"201","author":"Yokote","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2016.07.001_bib25","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.clinthera.2008.05.017","volume":"30","author":"Sasaki","year":"2008","journal-title":"Clin. Ther."},{"key":"10.1016\/j.atherosclerosis.2016.07.001_bib26","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1507\/endocrj.K10E-289","article-title":"Comparative study between high-dose fluvastatin and low-dose fluvastatin and ezetimibe with regard to the effect on endothelial function in diabetic patients","volume":"58","author":"Kawagoe","year":"2011","journal-title":"Endocr. J."},{"key":"10.1016\/j.atherosclerosis.2016.07.001_bib27","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1253\/circj.CJ-10-1281","article-title":"Randomized head-to-head comparison of pitavastatin, atorvastatin, and rosuvastatin for safety and efficacy (quantity and quality of LDL): the PATROL trial","volume":"75","author":"Saku","year":"2011","journal-title":"Circ. J."},{"key":"10.1016\/j.atherosclerosis.2016.07.001_bib28","doi-asserted-by":"crossref","first-page":"879","DOI":"10.5551\/jat.4176","article-title":"Association between lowering low-density lipoprotein cholesterol with pravastatin and primary prevention of cardiovascular disease in mild to moderate hypercholesterolemic Japanese","volume":"17","author":"Teramoto","year":"2010","journal-title":"J.\u00a0Atheroscler. Thromb."},{"key":"10.1016\/j.atherosclerosis.2016.07.001_bib29","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.curtheres.2005.12.008","article-title":"Effects of simvastatin 20 mg\/d on serum lipid profiles in Japanese hyperlipidemic patients: a prospective, open-label pilot study","volume":"66","author":"Yoshida","year":"2005","journal-title":"Curr. Ther. Res. Clin. Exp."},{"key":"10.1016\/j.atherosclerosis.2016.07.001_bib30","doi-asserted-by":"crossref","first-page":"108","DOI":"10.5551\/jat.13.108","article-title":"Efficacy of a low dose of pitavastatin compared with atorvastatin in primary hyperlipidemia: results of a 12-week, open label study","volume":"13","author":"Yoshitomi","year":"2006","journal-title":"J.\u00a0Atheroscler. Thromb."},{"key":"10.1016\/j.atherosclerosis.2016.07.001_bib31","doi-asserted-by":"crossref","DOI":"10.1093\/ehjcvp\/pvw006","article-title":"Variability of low-density lipoprotein cholesterol response with different doses of atorvastatin, rosuvastatin, and simvastatin: results from VOYAGER","author":"Karlson","year":"2016","journal-title":"Eur. Heart J. Cardiovasc Pharmacother."},{"key":"10.1016\/j.atherosclerosis.2016.07.001_bib32","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.atherosclerosis.2015.03.004","article-title":"Variability of the LDL-C lowering response to ezetimibe and ezetimibe\u00a0+ statin therapy in hypercholesterolemic patients","volume":"240","author":"Descamps","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2016.07.001_bib33","doi-asserted-by":"crossref","first-page":"295","DOI":"10.2169\/internalmedicine.52.9054","article-title":"Status of dyslipidemia treatment in Japanese adults: an analysis of the 2009 Japan Society of Ningen Dock database","volume":"52","author":"Takahashi","year":"2013","journal-title":"Intern Med."},{"key":"10.1016\/j.atherosclerosis.2016.07.001_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.curtheres.2012.02.001","article-title":"Cross-sectional survey to assess the status of lipid management in high-risk patients with dyslipidemia: clinical impact of combination therapy with ezetimibe","volume":"73","author":"Teramoto","year":"2012","journal-title":"Curr. Ther. Res. Clin. Exp."},{"key":"10.1016\/j.atherosclerosis.2016.07.001_bib35","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1177\/1741826710397100","article-title":"Lipid-lowering treatment in hypercholesterolaemic patients: the CEPHEUS Pan-Asian survey","volume":"19","author":"Park","year":"2012","journal-title":"Eur. J. Prev. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2016.07.001_bib36","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1001\/jama.295.2.180","article-title":"International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis","volume":"295","author":"Bhatt","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2016.07.001_bib37","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1370\/afm.1641","article-title":"Cardiovascular risk and statin use in the United States","volume":"12","author":"Johansen","year":"2014","journal-title":"Ann. Fam. Med."}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915016303008?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915016303008?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,7,12]],"date-time":"2018-07-12T13:35:16Z","timestamp":1531402516000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915016303008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":37,"alternative-id":["S0021915016303008"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2016.07.001","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low-density lipoprotein cholesterol levels and lipid-modifying therapy prescription patterns in the real world: An analysis of more than 33,000 high cardiovascular risk patients in Japan","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2016.07.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Authors. Published by Elsevier Ireland Ltd.","name":"copyright","label":"Copyright"}]}}